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Abstract Drug allergy is an inlportant co:mplication in the
use of agents such as penicillins, cephalosporins,
sulphona:mides, insulin and streptokinase. The
allergenic properties of drugs are a function of
:molecular size and che:mical reactivity. Factors
deter:mining an individual's risk of an allergic
response are not fully understood but include
genetic predisposition, prior exposure, route of
ad:ministration, drug dosage, age and conco:mitant
disease.
The :most dangerous but least co:m:mon for:m of
drug allergy is generalised anaphylaxis. The
:majority of reactions are non-anaphylactic and
involve the skin, with a lesser incidence of hae:ma-
tological, renal, :musculoskeletal, cardiorespira-
tory and other syste:mic :manifestations.
The only definitive test for allergy in a patient
with a history of previous allergic reaction is
rechallenge, a dangerous and seldo:m indicated
procedure. An alternative is skin testing, but this
requires an experienced practitioner and has
intrinsic risk. In vitro testing :may be of value in
predicting the risk ofrechallenge.
Safe use of a suspect drug requires a careful
assess:ment ofrisk and a cautious approach. Use of
an offending drug in a high-risk patient is rarely
indicated, but if it is considered essential, initial
therapy or desensitisation in an intensive care
environ:ment is reco:m:mended.
S Air Med J 1994; 84:.281-286.
D rugs are an important cause of morbidity andmortality in modern medicine, with adversedrug reactions (ADRs) responsible for at least
1% of hospital admissions. I .
Most ADRs are due to dose-related toxicity. A small
proportion are hypersensitivity reactions which are not
directly dose-related and due to aberrant drug kinetics
or individual patient sensitivity. Drug allergy (immune-
mediated hypersensitivity) accounts for 5 - 10% of
ADRs2.' (Fig. 1).
Few drugs are likely to be antigenic. Most drugs are
too small (molecular weight (MW) < 1 000) to be com-
plete antigens and have a stable chemical nature pre-
venting the conjugation with carrier molecules necessary
for function as a hapten.' Metabolites of J3-lactam
antibiotics are an exception, with spontaneous disrup-
tion of the J3-lactarn ring yielding reactive groups which
readily haptenate proteins to form complete antigens.'
Most clinically important drug allergy and over 80% of
life-threatening allergic reactions are caused by peni-
cillin.3,7
Although sporadic drug allergy has been described
for almost all drugs used, it is only a consistent risk for
the J3-lactarns, sulphonamides and larger molecules such
as insulin and streptokinase. The mechanism of
sulphonamide allergy is poorly understood.s Several
groups of drugs may cause clinical anaphylaxis in sus-
ceptible patients by a mechanism which does not
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involve immune recognition and antibody production;
this phenomenon is thus not truly allergic in nature.
Opiates,' non-steroidal anti-inflammatory drugs
(NSAIDs)4 and radiographic contrast media cause
direct mast cell degranulation and mediator release.
IgG aggregates in administered immunoglobulin can
activate complement components. 5 Activated .comple-
ment factors C3a and C5a may then activate mast cells,
causing an anaphylactic reaction.S,9,IO
This review will discuss the mechanisms and epi-
demiology of drug allergy, with special reference to
penicillin, and will suggest strategies for safer use of J3-
lacrarn antibiotics.
The mechanism of drug allergy
The tripeptide analogue penicillin (MW 356) degrades
spontaneously in solution with opening of the J3-lactarn
ring to form the penicilloyl group. Ten per cent of a
dose will be degraded to metabolites iliat combine co-
valently with the lysine residues of serum tissue, mem-
brane and microbial-derived proteins to form complete
antigens. 3",1I The penicilloyl-protein carrier molecules
are designated the 'major determinants' because they
comprise 95% of the penicillin metabolites. The remain-
ing 5% comprise several metabolites known collectively
as the 'minor determinants' (Fig. 2). These terms refer
only to the proportion of metabolites formed and not to
their potency. Minor determinants are believed to be
mainly responsible for severe acute allergic reac-
tions,>,3,I2,l3 while major determinant metabolites are
more likely to elicit the lesser non-immediate penicillin
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Similar reactions occur with the semisynthetic peni-
cillins. Penicillin metabolite antigen can also fonn in
vitro. Penicillin merabolites fonned spontaneously in
solution can polymerise or bind proteins involved in the
manufacturing fermentation process to form anti-
gens.'·Il·" Current manufacturing procedures remove
most but not all potential carrier molecules!"I Use of
freshly prepared drug will decrease the incidence and
severity of adverse reactions. 14
The reason why antigen formation, a pathological
immune response, and allergic reaction occur in only
some exposed patients is unknown. Drug allergy is likely
to have multifactorial causation involving genetic heri-
tage, individual susceptibility, the variables of drug
administration and concomitant disease.
Factors determining risk
Genetic
There is familial predisposition to drug allergy, which in
mice has been shown to be unrelated to MHC alleles.6
The incidence of drug allergy is not increased in patients
with atopy, however/,,·7.s.I5 but anaphylaxis, if it occurs,
tends to be more severe'-'
Individual predisposition
ADRs to all drugs are 3 times more common· in patients
with a previous history of penicillin allergy." The risk of
a f3-lactam allergic reaction is 4 - 6 times higher in
patients with a previous history of penicillin allergy but
will still only occur in a minority of these patients.
Those at risk cannot be reliably identified in advance.
Accurate assessment of history is difficult, and non-
allergic drug reactions are often misdiagnosed. The pre-
dictive value of a positive history is further limited by
the decreased response to antigen \\~th time. I6.17 Skin
reaction positivity decreased with time in one studyIS
from over 90% at 6 months after an anaphylactic reac-
tion to 22% when tested 10 years later. The risk of ana-
phylaxis in patients with a history of a non-anaphylactic
allergic reaction is not known.
The predictive value of a history of no allergic
response to previous penicillin use is of limited value.
Most serious and fatal reactions occur in patients with
no previous history of allergy.2,7." Previous drug expo-
sure cannot be excluded by history alone, because the
patient might be unaware of intra-uterine or environ-
mental sensitisation by milk and aerosol. 11,19
Drug administration
Allergy is not conventionally considered a dose-related
reaction, but the intensity and duration of drug admini-
stration may determine the nature of the immune
response. Sensitisation due to short-term low-dose
exposure tends to cause the production of specific IgB.'·6
Subsequent triggering of an immediate-type reaction
may require a higher drug dose. There is a higher inci-
dence of anaphylaxis after parenteral administration.2,7
Only 6 cases of death due to anaphylaxis after oral
therapy have been reponed, while the risk of non-fatal
anaphylaxis is less than half that for parenteral drug. 17
High concentrations of penicillin metabolites may be
required for the degree of 19B cross-binding necessary
for rapid mast cell activation and degranulation. ;
High-dose prolonged drug use tends to result in an
IgG-mediated response!·6 The risk of serum sickness,
interstitial nephritis and leukopenia increases \\~th dose
and duration of therapy. Chronic low-dose exposure to
parenteral depot penicillin does not seem to increase the
risk of an allergic reaction. A study of the use of prophy-
lactic benzathine penicillin in a young population
showed that anaphylaxis and rates of skin test positivity
were no higher than for patients receiving single-dose
therapy for sexually transmitted diseases.'o
Age
The incidence of penicillin allergy is highest in adults
and tends to decrease towards the extremes of age. I9
. Penicillin and arninopenicillin are commonly prescribed
for children, and the gastro-intestinal and cutaneous
reactions which occur may be labelled as allergic. 15 The
true incidence of allergy in children is far lower than that
in adults. 15 Children are also less likely to show sensitisa-
tion on skin testing after a reaction. 15,17 Type I reactions
are rare in children, even those with a history of cuta-
neous reactions to penicillin. 1;,21
. Infection
Antigen presentation during infection may be influenced
by endotoxin-induced production of tumour necrosis
factor (ThTF), interleukin-l (IL-l) and other cytokines.
In addition, micro-organisms may release 'super-
carrier' molecules capable of binding multiple drug
molecules to form potent antigens.;
Classification of mechanisms of allergy
Accurate classification is difficult. Diagnosis is often
uncertain and the responsible immune mechanism
unclear. Despite the problem of overlap of mechanisms
the classification system described by Gell and Coombs
is still widely used.' The four groups are: type 1-
immediate hypersensitivity; type IT - cytotoxic anti-
bodies; type lIT - immune complex; and type IV -
cell-mediated.
Type I
IgE production is a necessary but not a sufficient pre-
condition. Although exposure to penicillin metabolite
protein conjugates results in the production of antigen-
specific IgE in 10 - 15% of patients recei\~g prolonged
high-dose therapy, few of these will have type I reactions




:;;;;;ilI;;;;;;;aiil;;.;;:.1L -------- Ig E
,"-'1,.------- Fc E RI
,.-\- cell membrane
l}-+I------- granules
CARRIER -HAPTEN CONJUGATE BINDING
CAUSES RECEPTOR CROSS LINKING
FIG. 3.
Mast cell.
The IgE antibody response to antigen is idiosyncratic
and cannot be predicted or explained in an individual by
currently available methods. B-Iymphocyre class-switch-
ing from IgM and IgG to IgE production may be the
principal aetiological step. This is regulated by inter-
leukin-4 (IlA) produced by helper T Iymphocyres (TH).
A subgroup of TH cells have. receptors for the
constant region of IgE (Fc E R) and synthesise and
release IgE-potentiating and inhibiting factors! IgE iso-
type switching and activation of IgE memory cells is
enhanced by TH2 produced IL-4 and suppressed by
T HI-produced prostaglandin E interferon-et2 and inter-
feron--y! A berrer understanding of determinants of the
TH2:THl ratio may provide the key to the management
of acute allergic reactions."
Re-exposure to the antigen may cause IgE-mediated
mast cell and basophil degranulation. Degranulation
requires cross-linking of the high-affinity specific IgE Fc
receptor I (Fc E RI) on mast cells and basophils. Each
basophil or mast cell has approximately 10' Fc E RI
molecules.'o Cross-linking occurs when the antigenic
determinants of the hapten bound to the carrier
molecule bind drug-specific IgE on the mast cell sur-
face. Multivalent carrier molecules (multiple penicillin
molecules bound to carrier molecule) cause Fc E RI
aggregation in the cell membrane and cell activation"
(Fig. 3). This occurs with cross-linking of less than 1%
« 100 molecules/cell) of total surface IgE.'o Anti-IgE
antibodies and mitogen can also activate the Fc E RI. '0
Cross-linking initiates a complex series of membrane
and intracellular events culminating in degranulation
and release of mediator molecules.
Activated complement components C3a and C5a
activate mast cells directly by binding distinct surface
receptors. Morphine, dextran, mannitol and contrast
media (hypertonic solutions) and polylysine also cause
direct mast cell activation. 8"o The mechanism of
NSAID-induced anaphylaxis is uncenain.
Mast cell and basophil activation cause an imme-
diate, intermediate or delayed-onset reaction of a
generalised or localised nature. Mast cell degranulation
occurs rapidly after activation and is not cyrotoxic to
the degranulating cell. 'o The primary (granule-stored)
mediators in the human are histamine, eosinophil and
neutrophil chemotactic factors, proteases and heparin.""O
Histamine, which comprises 10% of granular content by
weight," is the fastest-acting and most important media-
tor" causing bronchoconstriction, vasodilation, increased
vascular permeab.ility, and goblet cell mucus secretion.""
Vasodilation may be mediated by histamine-induced
release of nitric oxide from endothelial cells.' Activated
mast cells also synthesise and release TNF, IL-l, 2, 3,
4, 5 and 6, prostaglandins, leukorrienes arid granulocyre
macrophage colony-stimulating factor.°""o 'D\TF and IL-
I may have a role in the causation of the shock of acute
anaphylaxis. Cyrokines are the principal mediators of
the intermediate and delayed inflammatory responses.
The effect of mast cell/basophil activation depends
on the number and anatomical site of effector cells.
Generalised activation \vith release of mediators into the
circulation causes anaphyla.xis, the least frequent but
most serious of all ADRs.' Symptoms begin within
minutes, peak at 15 - 30 minutes and resolve within
hours.' Biphasic reactions do occur but are rare. 8
Localised mediator release results in exanthems,
urticaria, bronchospasm and hayfever. Urticaria and
pruritic skin reactions are the most common manifesta-
tion ofIgE-mediated allergy."
Type II
Antigen is formed after nonspecific adsorption of drug
onto cell membranes by binding to cell membrane pro-
tein." This may evoke immune sensitisation with pro-
duction of specific IgG antibodies. Cell-bound antibody
can activate, complement and bind the Fc receptor
of macrophages, neutrophils,. platelets, eosinophils, and
the large granular lymphocyres, i.e. NK and K cells"
Activation of these cells may result in a cytotoxic
response.
Type IT reactions are a rare but important cause of
haemolysis with use of penicillins and cephalosporins.
Cephalosporins have lower affinity for red blood cell
binding and cause fewer reactions." The incidence is
markedly increased in renal failure, suggesting a dose-
related mechanism.'
Penicillin-specific antibodies reacting with tubular
basement membrane occur in patients with interstitial
nephritis.' An aetiological role has not been established
and this may be an epiphenomenon.
Type ID
Prolonged exposure to high-dose intravenous penicillin
frequently causes the production of penicilloyl-specific
IgG! Immune complexes formed are usually efficiently
cleared by the reticulo-endothelial system. Failure of
clearance may result in deposition of immune com-
plexes in basement membranes with activation of com-
plement and/or a cellular immune response resulting in
rash, vasculitis, nephritis, arthritis and haemolysis.' The
clinical spectrum of disease ranges from mild exanthems
to life-threatening serum sickness.
Type IV
This type of reaction usually occurs when drug binding
to skin protein elicits a cell-mediated immune
response." Severe clinical problems are rare. Reactions
may complicate frequent skin exposure to drugs and are
an occupational hazard for nursing and pharmacy staff.
Fixed drug reaction may be a type IV immune
response.
Other reactions
Procaine penicillin use may be complicated by an
acute reaction characterised by a feeling of impending
doom, anxiety, violent and psychotic behaviour,
seizures, vertigo and tinnitus, hypo- or hypertension,
tachycardia, cardiovascular collapse and sudden death.
This is due to toxic and/or embolic effects following
inadvertent intravenous entry of the drug suspension.,,2.





wrfwt) and in blood forms 5 - 100 J.UIl aggregates which
cause pulmonary and cerebral embolisation." The pro-
caine content of procaine penicillin (6%) is sufficient to
cause neuro- and cardiotoxicity.24
The duration of clinical features does not usually
exceed 15 minutes. Incidence is 1 - 3/1 000 injections
and risk increases with dose." Distinction from gene-
ralised anaphylaxis is essential because management is
supportive and the use of adrenaline can be dangerous. 'I
Anlinopenicillins may cause a maculopapular rash,
probably due to the di-amino-acyl side-chain' and not
associated with IgE-mediated f3-lactam allergy." The
mechanism of this reaction is uncertain. Amino-
penicillin-specific IgM and IgG are found in some
patients' but have not been demonstrated to have a role
in the reaction, which may be toxic in nature."
The risk of rash is markedly increased (> 90%) in
patients with acute infectious mononucleosis given
aminopenicillins." Patients with chronic renal failure,
gOut and lymphocytic blood dyscrasias are also at
increased risk. 3
Penicillin is well tolerated in these patients on re-
exposure,14 but the latter may be dangerous because def-
inite initial differentiation from a penicillin reaction is
not possible.
Epidemiology
The incidence of allergic reactions to drugs is difficult to
determine. There is a bias towards reporting the severe
and especially the fatal events, together with inadequate
reporting of adverse events from the developing regions
of the world where the penicillins are extensively used.
With a few notable exceptions, most studies are from
the developed world. Many date from the 1950s and
1960s when there was a lesser tendency to discriminate
between ADRs of allergic and non-allergic cause.
Up to 5% of the general population' and up to 20%
of hospital patients claim a history of penicillin allergy."
Current data suggest that its true overall incidence is
between 0,7% and 8%.'·'0 The most common allergic
manifestation is urticaria and about half of all allergic
reactions are dermatological. 13,2'
Generalised anaphylaxis occurs in 0,004 - 0,015% of
treatment procedures.'" Less than 50% of reactions are
severe' and 10% are fatal (1/50 000 - 100 000 treatment
procedures);I.",,18 88,7 - 96% of fatal anaphylactic reac-
tions occur within 1 hour of drug administration.",,18
Over half of the deaths due to penicillin-induced ana-
phylaxis occur in patients with no previous history of
penicillin allergy. 14
Cross-reactivity does occur between penicillins and
cephalosporins. While primary cephalosporin allergy is
rare/" penicillin-allergic patients receiving first- and
second-generation cephalosporins have a 4 - 6 times
higher incidence of allergy, which is reponed to range
from 8% to 16%.1,3,7,1' Some cephalosporins (e.g. cepha-
lothin) tend to cause more allergic reactions, possibly
because of reactions to side-chain epitopes.' The con-
tamination of early preparations of cephalosporins by
small amounts of penicillin synthesised by the cephalo-
sporidium mould may have been a reason for the higher
incidence of cross-reactivity initially reponed." The
extent of cross-reactivity between penicillins and third-
generation cephalosporins is controversial and clinical
experience suggests that it is uncommon. Some studies
have suggested that there is no increase in the risk of
allergy to third-generation cephalosporins in penicillin-
allergic patients. I However, the antigenic properties of
the shared f3-lactam ring (Fig. 4) suggests that some
degree of cross-reactivity is likely. Half of the few
recorded cases of anaphylactic reactions to third-genera-

















previous history of penicillin allergy. I' The carbapenems
have significant immune cross-sensitivity with
penicillin.'"
.Testing for allergy
The only cenain test for drug allergy is rechallenge. This
can be dangerous and is unethical unless use of the drug
is essential. Alternative tests for drug allergy are cur-
rently unsatisfactory. Allergenic metabolites and the
. mechanism and determinants of the allergic response
are unknown. Penicillin anaphylaxis is believed to be
due to the minor determinants, but the metabolite
responsible for cephalosporin allergy is not known.
Skin tests
Skin tests assess the cutaneous response to intradermal
injection of penicillin metabolites. The method is not
universally accepted as reliable and should only be done
by an experienced practitioner." Optimal results require
the use of both major and minor determinants.' The
major determinant, conjugated preparation benzylpeni-
cilloyl-polylysine (20 lysine and 12 - 15 penicilloyl
groups per conjugate complex) (PPL), is produced
commercially but is not freely available in South Africa.
The more imponant minor determinant mixture (ben-
zylpenicilloate - a mixture of benzylpenilloate and ben-
zylpenicilloylamine) (MDM) is an unstable solution
which cannot easily be prepared in the required conju-
gate-linked multivalent farmY' MDM is commercially
available in Europe but not the USA." Benzylpenicillin,
hydrolysed metabolites and spontaneous degradation
products occurring in solution are used as MDM sub-
stitutes. Testing with only the major determinant will
result in failure to detect 5 - 10% of positive skin tests.,,12
Skin testing has an inherent risk. Slow diffusion of
PPL from injection site has been implicated in systemic
reactions, which occur in less than 1% of patients
tested.' At least 3 deaths after skin testing have been
reponed."!'
•
Skin testing may give a false-negative result if per-
formed while the patient is taking antihistamines (H,-
antagonists), tricyclic antidepressants or sympatho-
mimetic drugs2or during serious illness.'2
Results of large studies suggest a high negative and a
lower positive predictive value. Of patients with a history
of a previous penicillin reaction, 7 - 35% will have posi-
tive skin tests using PPL and an MDM preparation.
Children tend to have a lower positive response rate
than adults.7 Of skin test-positive subjects, 9 - 70% will
have an allergic reaction on penicillin challenge.2.1• The
wide response range is due to the small number of sub-
jects in each study, referral bias and variation in popula-
tions and testing methods used. I. The positive predictive
value in patients with a positive history is 50 - 70%.
This implies that at least 30% of patients with penicillin-
specific IgE antibodies, as detected by skin testing, do
not react to penicillin. 22
Of history-positive, skin test-negative patients, 1 -
3% \vill have an allergic response. In most this will be
mild and limited to the skinY· A negative skin response
to PPL and MDM effectively means that there is no
increased risk of an immediate life-threatening allergic
reaction.' The negative predictive value for penicillin
skin testing in patients with prior history of penicillin
allergy is 99% for reactions of clinical significance.22
There is no role for skin testing in patients with no
previous history of penicillin allergy. The negative pre-
dictive value of a negative skin test in a patient with no
, history of allergy is 99,5%, which is not significantly dif-
ferent from the negative predictive value of a negative
history.22 A strongly positive reaction on skin testing for
penicillin allergy has a positive predictive value of
between 6% and 10% in patients with no previous
history of allergy."'· Use of the skin testing will not
significantly decrease the risk of an allergic reaction to
penicillin.
Skin tests should only be done at the time that penci-
cillin therapy is required. Testing cannot be performed,
in anticipation of furore use because the test is immuno-
genic and sensitivity can change with time. Results are
not considered valid for more than 24 hours." Penicillin
skin tests do not reliably predict the risk of a cephalo-
sporin reaction,27,2. for which there are no validated skin
tests. I'
Radio-allergosorbent test (RAST)
The RAST is used to detect penicilloyl-specific IgE in
serum. There are no generally available tests for minor
determinants."·15 Results correlate well with those of
skin testing.2.' False-positive results can be due to non-
specific binding associated with high serum IgE levels
and blocking antibodies can cause false-negative results.'
The major advantage of the RAST is safety, since the
patient is not exposed to penicillin metabolites, and the
major disadvantage is delay before results are available.
Other in vitro tests
Measurement of antigen-specific IgM and IgG is
only of value in the investigation of drug-related throm-
bocytopenia, haemolytic anaemia and granulocyto-
penia.'
In basophil degranulation tests histamine release
is measured after exposing fresh leucocyres to antigen in
vitro. The assay is laborious, of limited availability and
less valuable than skin testing or RASTY'
Lym.phocyte transformation and macrophage
inhibition factor assays are slow and laborious and
have poor reproducibilityY'·'· They have little clinical
value.
Histamine, prostaglandin D, (PGD,) and
tryptase levels. Serum histamine and PGD, and their
urinary metabolites are elevated for a short period after
an episode of anaphylaxis. Their levels can be measured
to confirm the diagnosis. Mast cell-derived serum
tryptase levels remain elevated for a longer period and
provide direct evidence of mast cell degranulation."·
Levels correlate bener with the clinical presentation
than do those of histamine and PGD,.'
Safe use of a suspect drug
The prospective assessment of individual risk of drug
allergy is difficult. History-taking is a nonspecific cost-
effective screening test which helps to avoid dangerous
drug use at the expense of excluding the use of effective
drugs which may be safe. Patients with no history of
pencillin allergy can be treated with pencillins without
further investigation. No currently available tests will
increase the safety of use. Awareness of the risk of ana-
phylaxis in this group may save lives, however, and par-
enteral penicillin should never be administered if trained
staff and basic resuscitation equipment are not available
(Fig. 5). Patients with a history of pencillin allergy
should ideally not receive penicillin, because the only
certain test of safety is rechallenge, which is intrinsically
dangerous." Cephalosporins should only be used when
necessary and where immediate resuscitation is
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Safe use of a suspect drug.
In certain circumstances the need for a pencillin is
sufficient to warrant furiller investigation of the safety of
use. The indication may be 'absolute', as in StrepWCOIXUS
viridans endocarditis, neurosyphilis, syphilis during
pregnancy or listerial meningitis, or 'relative', as in
meningococcal meningitis and rheumatic fever prophy-
laxis.
The recomm'endations for testing and drug use are
not well defined. Sensitivity should be assessed by skin
testing or a RAST. If this is negative, penicillin can be
started at full dose under careful observation (Fig. 6).
If tests are positive and therapy is still considered
essential, the patient should undergo desensitisation in
an intensive care unit. Protocols for this procedure are
well described.' Drug administration is started at a
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FIG. 6.
Sensitivity tests.
therapy. The mechanism of desensitisation is uncenain.
Incremental exposure may result in gradual and sub-
clinical mast cell degranulation; univalent antigen com-
plexes may bind IgE and block cross-linking and
degranulation;4 and the slow formation of low-valency
antigens may cause gradual cross-linking, degranulation'
and mediator depletion.' Therapy must be continuous
to maintain immune non-reactivity.
Premedication with antihistamines and/or conico-
steroids is of no proven value' but is advised by some
authors." About one-third of patients will expetience a
transient allergic reaction, which is usually mild.2
After antigen exposure ceases, mast cell reactivity
and clinical sensitivity return within I - 3 days.'
Generalised anaphylaxis requires immediate man-
agement with supponive therapy. The only therapeutic
drug of proven efficacy is subcutaneous adrenaline,
which is a physiological antagonist of mediator effects
and also acts to stabilise mast cells and basophils. 7
Corticosteroids have no effect for at least 1 hour and
there is no proven role for antihistamines.'
Conclusion
Allergic reactions are a well-publicised and imponant
but relatively rare complication of drug use.
The allergic reaction cannot be reliably predicted and
a conservative approach to patients with a history of
allergy is prudent. Allergy should be anticipated in all
patients who are treated with penicillin. Generalised
anaphylaxis is a potentially fatal reaction that can be
treated successfully.
The author wishes to thank Dr A. Robins for his help in
preparing the manuscript.
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